Biomarkers in rheumatology, now and in the future

David Gibson, Madeleine Rooney, Sorcha Finnegan, Ji Qiu, David Thompson, Joshua LaBaer, Stephen Pennington, Mark Duncan

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

This review examines the biomarker development process by using rheumatic disorders as the disease model for discussion. We evaluate the current role of biomarkers in the practice of rheumatology and discuss their likely role in the future. We define the essential components of the biomarker development pipeline and discuss the issue of fitness for purpose, i.e. what the biomarker(s) might offer in a clinical setting. As a component of this review we also highlight several emerging technologies that are beginning to provide practical solutions to support biomarker validation. In the process, we highlight some scenarios where additional biomarkers would add considerable value to clinical practice, and we review appropriate methods for each. We also emphasize some important but infrequently discussed considerations, includingthe need for protein variant verification. Ultimately, the adroit application of the methods of proteomics will transform the practice rheumatology and allow personalized clinical practice to become a reality.
LanguageEnglish
Pages423-433
JournalRheumatology (Oxford)
Volume51
Publication statusPublished - 2012

Fingerprint

Rheumatology
Biomarkers
Proteomics
Technology
Proteins

Cite this

Gibson, D., Rooney, M., Finnegan, S., Qiu, J., Thompson, D., LaBaer, J., ... Duncan, M. (2012). Biomarkers in rheumatology, now and in the future. Rheumatology (Oxford), 51, 423-433.
Gibson, David ; Rooney, Madeleine ; Finnegan, Sorcha ; Qiu, Ji ; Thompson, David ; LaBaer, Joshua ; Pennington, Stephen ; Duncan, Mark. / Biomarkers in rheumatology, now and in the future. In: Rheumatology (Oxford). 2012 ; Vol. 51. pp. 423-433.
@article{a04081f691f94c97ad3cea8bd82bad56,
title = "Biomarkers in rheumatology, now and in the future",
abstract = "This review examines the biomarker development process by using rheumatic disorders as the disease model for discussion. We evaluate the current role of biomarkers in the practice of rheumatology and discuss their likely role in the future. We define the essential components of the biomarker development pipeline and discuss the issue of fitness for purpose, i.e. what the biomarker(s) might offer in a clinical setting. As a component of this review we also highlight several emerging technologies that are beginning to provide practical solutions to support biomarker validation. In the process, we highlight some scenarios where additional biomarkers would add considerable value to clinical practice, and we review appropriate methods for each. We also emphasize some important but infrequently discussed considerations, includingthe need for protein variant verification. Ultimately, the adroit application of the methods of proteomics will transform the practice rheumatology and allow personalized clinical practice to become a reality.",
author = "David Gibson and Madeleine Rooney and Sorcha Finnegan and Ji Qiu and David Thompson and Joshua LaBaer and Stephen Pennington and Mark Duncan",
year = "2012",
language = "English",
volume = "51",
pages = "423--433",
journal = "Journal of Rheumatology",
issn = "0315-162X",

}

Gibson, D, Rooney, M, Finnegan, S, Qiu, J, Thompson, D, LaBaer, J, Pennington, S & Duncan, M 2012, 'Biomarkers in rheumatology, now and in the future', Rheumatology (Oxford), vol. 51, pp. 423-433.

Biomarkers in rheumatology, now and in the future. / Gibson, David; Rooney, Madeleine; Finnegan, Sorcha; Qiu, Ji; Thompson, David; LaBaer, Joshua; Pennington, Stephen; Duncan, Mark.

In: Rheumatology (Oxford), Vol. 51, 2012, p. 423-433.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Biomarkers in rheumatology, now and in the future

AU - Gibson, David

AU - Rooney, Madeleine

AU - Finnegan, Sorcha

AU - Qiu, Ji

AU - Thompson, David

AU - LaBaer, Joshua

AU - Pennington, Stephen

AU - Duncan, Mark

PY - 2012

Y1 - 2012

N2 - This review examines the biomarker development process by using rheumatic disorders as the disease model for discussion. We evaluate the current role of biomarkers in the practice of rheumatology and discuss their likely role in the future. We define the essential components of the biomarker development pipeline and discuss the issue of fitness for purpose, i.e. what the biomarker(s) might offer in a clinical setting. As a component of this review we also highlight several emerging technologies that are beginning to provide practical solutions to support biomarker validation. In the process, we highlight some scenarios where additional biomarkers would add considerable value to clinical practice, and we review appropriate methods for each. We also emphasize some important but infrequently discussed considerations, includingthe need for protein variant verification. Ultimately, the adroit application of the methods of proteomics will transform the practice rheumatology and allow personalized clinical practice to become a reality.

AB - This review examines the biomarker development process by using rheumatic disorders as the disease model for discussion. We evaluate the current role of biomarkers in the practice of rheumatology and discuss their likely role in the future. We define the essential components of the biomarker development pipeline and discuss the issue of fitness for purpose, i.e. what the biomarker(s) might offer in a clinical setting. As a component of this review we also highlight several emerging technologies that are beginning to provide practical solutions to support biomarker validation. In the process, we highlight some scenarios where additional biomarkers would add considerable value to clinical practice, and we review appropriate methods for each. We also emphasize some important but infrequently discussed considerations, includingthe need for protein variant verification. Ultimately, the adroit application of the methods of proteomics will transform the practice rheumatology and allow personalized clinical practice to become a reality.

M3 - Article

VL - 51

SP - 423

EP - 433

JO - Journal of Rheumatology

T2 - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

ER -

Gibson D, Rooney M, Finnegan S, Qiu J, Thompson D, LaBaer J et al. Biomarkers in rheumatology, now and in the future. Rheumatology (Oxford). 2012;51:423-433.